Photo of David G. Nathan,  MD

David G. Nathan, MD

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute
Phone: (617) 632-2155
Fax: (617) 632-2161


david_nathan@dfci.harvard.edu

David G. Nathan, MD

Dana-Farber Cancer Institute

EDUCATIONAL TITLES

  • Robert A Stranahan Distinguished Professor of Peds, Pediatrics, Harvard Medical School

Research Abstract

The pathophysiology and treatment of congential bone marrow failure and red cell syndromes.

Publications

Powered by Harvard Catalyst
  • Archer NM, Shmukler BE, Andolfo I, Vandorpe DH, Gnanasambandam R, Higgins JM, Rivera A, Fleming MD, Sachs F, Gottlieb PA, Iolascon A, Brugnara C, Alper SL, Nathan DG. Hereditary xerocytosis revisited. Am J Hematol 2014. PubMed
  • Sankaran VG, Ghazvinian R, Do R, Thiru P, Vergilio JA, Beggs AH, Sieff CA, Orkin SH, Nathan DG, Lander ES, Gazda HT. Exome sequencing identifies GATA1 mutations resulting in Diamond-Blackfan anemia. J Clin Invest 2012; 122:2439-43. PubMed
  • Bunn HF, Nathan DG, Dover GJ, Hebbel RP, Platt OS, Rosse WF, Ware RE. Pulmonary hypertension and nitric oxide depletion in sickle cell disease. Blood 2010; 116:687-92. PubMed
  • Nathan DG, Orkin SH. Musings on genome medicine: Hepatitis C. Genome Med 2010; 2:4. PubMed
  • Nathan DG, Orkin SH. Musings on genome medicine: cholesterol and coronary artery disease. Genome Med 2009; 1:60. PubMed
  • Nathan DG, Orkin SH. Musings on genome medicine: the Obama effect redux. Genome Med 2009; 1:86. PubMed
  • Nathan DG, Orkin SH. Musings on genome medicine: enzyme-replacement therapy of the lysosomal storage diseases. Genome Med 2010; 1:114. PubMed
  • Nathan DG, Orkin SH. Musings on genome medicine: Crohn's disease. Genome Med 2010; 1:103. PubMed
  • Nathan DG, Orkin SH. Musings on genome medicine: the slow but inexorable process of medical care reform in the United States. Genome Med 2009; 1:94. PubMed